Aptus Pharma Ltd
₹
None%
- close price
About
Key Points
- Market Cap ₹ 48.0 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 15.5
- Book Value ₹
- Dividend Yield %
- ROCE 38.2 %
- ROE 70.9 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 51.8 days to 36.4 days
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 13.90 | 17.81 | 24.56 | |
| 13.28 | 16.27 | 19.71 | |
| Operating Profit | 0.62 | 1.54 | 4.85 |
| OPM % | 4.46% | 8.65% | 19.75% |
| 0.00 | 0.03 | 0.08 | |
| Interest | 0.14 | 0.24 | 0.47 |
| Depreciation | 0.18 | 0.21 | 0.27 |
| Profit before tax | 0.30 | 1.12 | 4.19 |
| Tax % | 33.33% | 28.57% | 26.01% |
| 0.19 | 0.80 | 3.10 | |
| EPS in Rs | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 288% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 71% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.30 | 0.30 | 5.00 |
| Reserves | 0.67 | 1.47 | 1.97 |
| 2.22 | 5.31 | 10.35 | |
| 3.02 | 2.95 | 4.60 | |
| Total Liabilities | 6.21 | 10.03 | 21.92 |
| 0.52 | 0.63 | 0.99 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 5.69 | 9.40 | 20.93 | |
| Total Assets | 6.21 | 10.03 | 21.92 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.18 | -2.17 | -1.84 | |
| -0.35 | -0.30 | -0.54 | |
| 0.81 | 2.86 | 6.68 | |
| Net Cash Flow | 0.28 | 0.38 | 4.30 |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 63.02 | 68.66 | 83.82 |
| Inventory Days | 176.00 | 183.57 | 285.06 |
| Days Payable | 104.07 | 72.25 | 52.89 |
| Cash Conversion Cycle | 134.95 | 179.97 | 315.98 |
| Working Capital Days | 51.99 | 67.02 | 36.41 |
| ROCE % | 26.48% | 38.20% |
Documents
Annual reports
No data available.
Business Profile[1]
Aptus Pharma Limited is a Gujarat-based marketer and distributor of pharmaceutical formulations, operating in an asset-light model through contract manufacturing partners. It offers a diverse portfolio of 194 products across multiple therapeutic categories.